Vimarsana
Biggest News Aggregation in the World

Disability Status Scale News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Disability Status Scale. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Disability Status Scale Today - Breaking & Trending Today

BTK Inhibitor Reduces Brain Lesions in Relapsing MS - Vimarsana News

BTK Inhibitor Reduces Brain Lesions in Relapsing MS

Subgroup analysis shows brain penetration

Obesity Linked to Greater Disability, Poorer Outcomes in Multiple Sclerosis - Vimarsana News

Obesity Linked to Greater Disability, Poorer Outcomes in Multiple Sclerosis

For newly diagnosed patients with multiple sclerosis (MS), obesity is associated with higher disease severity and poorer outcomes.

Obesity Linked to Greater Disability, Poorer Outcomes in MS - Vimarsana News

Obesity Linked to Greater Disability, Poorer Outcomes in MS

For newly diagnosed patients with multiple sclerosis (MS), obesity is associated with higher disease severity and poorer outcomes.

Hippotherapy Simulation for Multiple Sclerosis Helps Mobility, Muscle Strength - Vimarsana News

Hippotherapy Simulation for Multiple Sclerosis Helps Mobility, Muscle Strength

Hippotherapy simulation may become a nonpharmacological intervention for people with MS that can improve muscle strength and spasticity.

Press Release : New data for Roche's OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis - Vimarsana News

Press Release : New data for Roche's OCREVUS (ocrelizumab) reinforce significant benefit on slowing disease progression in relapsing and primary progressive multiple sclerosis

Message : Required fields -- 85% of treatment-naïve, early-stage relapsing-remitting multiple sclerosis (RRMS) patients achieved no evidence of disease activity (NEDA) in open-label Phase IIIb ENSEMBLE study -- OCREVUS significantly slowed loss of brain tissue within T2 MRI lesions in primary progressive multiple sclerosis (PPMS) in post-hoc analysis of Phase III ORATORIO study -- OCREVUS-treated patients show highest adherence and persistence rates compared with other disease-modifying therapies (DMTs) in two-year U.S. claims analysis ...